Richard Hertzberg Net Worth

The estimated Net Worth of Richard Hertzberg is at least $670 Thousand dollars as of 9 August 2016. Richard Hertzberg owns over 21,000 units of Cellectar Biosciences Inc stock worth over $585,200 and over the last 9 years Richard sold CLRB stock worth over $85,260.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Richard Hertzberg CLRB stock SEC Form 4 insiders trading

Richard has made over 3 trades of the Cellectar Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Richard sold 21,000 units of CLRB stock worth $42,630 on 9 August 2016.

The largest trade Richard's ever made was buying 238,500 units of Cellectar Biosciences Inc stock on 15 April 2016 worth over $505,620. On average, Richard trades about 93,500 units every 39 days since 2016. As of 9 August 2016 Richard still owns at least 280,000 units of Cellectar Biosciences Inc stock.

You can see the complete history of Richard Hertzberg stock trades at the bottom of the page.

What's Richard Hertzberg's mailing address?

Richard's mailing address filed with the SEC is 1329 STRATFORD COURT, , DEL MAR, CA, 92014.

Insiders trading at Cellectar Biosciences Inc

Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm, and John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.

What does Cellectar Biosciences Inc do?

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p

Complete history of Richard Hertzberg stock trades at Cellectar Biosciences Inc

Cellectar Biosciences Inc executives and stock owners

Cellectar Biosciences Inc executives and other stock owners filed with the SEC include:

• James Caruso,
  President, Chief Executive Officer, Director
• James V. Caruso,
  Pres, CEO & Director
• Jarrod Longcor,
  Chief Business Officer
• Jarrod Longcor,
  Chief Operating Officer
• John Friend,
  Vice President, Chief Medical Officer
• Dov Elefant,
  Chief Financial Officer, Vice President
• Douglas Swirsky,
  Independent Chairman of the Board
• John Neis,
  Independent Director
• Stefan Loren,
  Independent Director
• Stephen Hill,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Gregory J. Lynch Esq.,
  Sec.
• Dr. Laurence Reilly L.L.M., LL.M, M.D., MBChB,
  Interim Chief Medical Officer
• Chad J. Kolean CPA, CPA,
  Chief Financial Officer
• Richard Hertzberg,
  
• Brian M Posner,
  Chief Financial Officer
• Igor D Grachev,
  Chief Medical Officer
• Jamey P Weichert,
  Chief Scientific Officer
• Paul L Berns,
  Director
• Investment Company, Inc. Awm,
  10% owner
• John Patrick Genn,
  VP of Business Development
• Cameron Szakacs,
  VP of Clinical Development
• Simon Pedder,
  President and CEO
• Austin W & Greenhouse David...,
  10% owner
• Asher Chanan Khan,
  Director
• Chad J Kolean,
  Chief Financial Officer
• Darrell Shane Lea,
  Chief Commercial Officer
• Andrei Shustov,
  Senior Vice President, Medical